Literature DB >> 16353927

Further advances in the synthesis of endocannabinoid-related ligands.

Anu Mahadevan1, Raj K Razdan.   

Abstract

Recent advances in the synthesis of endocannabinoid-related ligands for the period 2001-2004 are covered in this review. During this period the first solid phase synthesis of anandamide (AEA) analogs was developed, which allows modification at both the head group and the end pentyl chain. Synthesis of water-soluble prodrugs of noladin ether was reported, which are chemically stable, rapidly release noladin ether under enzymatic conditions and are shown to reduce intraocular pressure. The structure-activity relationships (SAR) of alkylcarbamic acid aryl esters and the discovery of potent archidonylsulfonyl derivatives as fatty acid amide hydrolase (FAAH) inhibitors are summarized. Recent synthetic developments in the controversial area of anandamide membrane transporter (AMT) inhibitors are also discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16353927      PMCID: PMC2750987          DOI: 10.1208/aapsj070250

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  23 in total

1.  SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.

Authors:  M Rinaldi-Carmona; F Barth; J Millan; J M Derocq; P Casellas; C Congy; D Oustric; M Sarran; M Bouaboula; B Calandra; M Portier; D Shire; J C Brelière; G L Le Fur
Journal:  J Pharmacol Exp Ther       Date:  1998-02       Impact factor: 4.030

Review 2.  Pharmacology of cannabinoid CB1 and CB2 receptors.

Authors:  R G Pertwee
Journal:  Pharmacol Ther       Date:  1997       Impact factor: 12.310

3.  2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor.

Authors:  L Hanus; S Abu-Lafi; E Fride; A Breuer; Z Vogel; D E Shalev; I Kustanovich; R Mechoulam
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-20       Impact factor: 11.205

4.  Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor.

Authors:  T Sheskin; L Hanus; J Slager; Z Vogel; R Mechoulam
Journal:  J Med Chem       Date:  1997-02-28       Impact factor: 7.446

Review 5.  Structure-activity relationships of anandamide, an endogenous cannabinoid ligand.

Authors:  A D Khanolkar; A Makriyannis
Journal:  Life Sci       Date:  1999       Impact factor: 5.037

Review 6.  Cannabimimetic fatty acid derivatives: the anandamide family and other endocannabinoids.

Authors:  V Di Marzo; T Bisogno; L De Petrocellis; D Melck; B R Martin
Journal:  Curr Med Chem       Date:  1999-08       Impact factor: 4.530

7.  Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor.

Authors:  Amy C Porter; John-Michael Sauer; Michael D Knierman; Gerald W Becker; Michael J Berna; Jingqi Bao; George G Nomikos; Petra Carter; Frank P Bymaster; Andrea Baker Leese; Christian C Felder
Journal:  J Pharmacol Exp Ther       Date:  2002-06       Impact factor: 4.030

8.  Molecular characterization of a peripheral receptor for cannabinoids.

Authors:  S Munro; K L Thomas; M Abu-Shaar
Journal:  Nature       Date:  1993-09-02       Impact factor: 49.962

9.  Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies.

Authors:  Marco Mor; Silvia Rivara; Alessio Lodola; Pier Vincenzo Plazzi; Giorgio Tarzia; Andrea Duranti; Andrea Tontini; Giovanni Piersanti; Satish Kathuria; Daniele Piomelli
Journal:  J Med Chem       Date:  2004-10-07       Impact factor: 7.446

Review 10.  Recent advances in the synthesis of endocannabinoid related ligands.

Authors:  R K Razdan; A Mahadevan
Journal:  Chem Phys Lipids       Date:  2002-12-31       Impact factor: 3.329

View more
  7 in total

Review 1.  Biosynthesis, degradation and pharmacological importance of the fatty acid amides.

Authors:  Emma K Farrell; David J Merkler
Journal:  Drug Discov Today       Date:  2008-04-03       Impact factor: 7.851

2.  Asymmetric synthesis of novel N-(1-phenyl-2,3-dihydroxypropyl)arachidonylamides and evaluation of their anti-inflammatory activity.

Authors:  Padmanabha V Kattamuri; Rebecca Salmonsen; Catherine McQuain; Sumner Burstein; Hao Sun; Guigen Li
Journal:  Life Sci       Date:  2012-07-20       Impact factor: 5.037

3.  Anti-proliferative effect of a putative endocannabinoid, 2-arachidonylglyceryl ether in prostate carcinoma cells.

Authors:  Kasem Nithipatikom; Marilyn A Isbell; Michael P Endsley; Jeffrey E Woodliff; William B Campbell
Journal:  Prostaglandins Other Lipid Mediat       Date:  2010-12-15       Impact factor: 3.072

Review 4.  A review of the interactions between alcohol and the endocannabinoid system: implications for alcohol dependence and future directions for research.

Authors:  Matthew J Pava; John J Woodward
Journal:  Alcohol       Date:  2012-03-27       Impact factor: 2.405

5.  Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors.

Authors:  Martin A Storr; Catherine M Keenan; Dominik Emmerdinger; Hong Zhang; Birol Yüce; Andrei Sibaev; Federico Massa; Nancy E Buckley; Beat Lutz; Burkhard Göke; Stephan Brand; Kamala D Patel; Keith A Sharkey
Journal:  J Mol Med (Berl)       Date:  2008-05-21       Impact factor: 4.599

Review 6.  Endocannabinoid regulation of matrix metalloproteinases: implications in ischemic stroke.

Authors:  Somnath Mukhopadhyay; David A Tulis
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2007-10

7.  Cannabinoid CB1 receptor recognition of endocannabinoids via the lipid bilayer: molecular dynamics simulations of CB1 transmembrane helix 6 and anandamide in a phospholipid bilayer.

Authors:  Diane L Lynch; Patricia H Reggio
Journal:  J Comput Aided Mol Des       Date:  2006-11-14       Impact factor: 4.179

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.